Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 54

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Cardiac amyloidosis

Not yet recruiting

Serum Transthyretin Levels in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis and Acoramidis: A Within‑Patient Pilot Crossover Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Medical University Of Vienna

Rheumatoid arthritis+1

Not yet recruiting

Phase II Study of 99mTc NTP15-5 Imaging to Detect Hand Joint Disease in Patients with Rheumatoid Arthritis and Finger Osteoarthritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Jean Perrin

VEXAS syndrome

Not yet recruiting

Randomized Study of SIR9900 for Safety and Effectiveness in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Amyloidosis

Not yet recruiting

Evaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic lupus erythematosus

Not yet recruiting

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

HIV infection

Not yet recruiting

Durable HIV-1 control with 10-1074-LS, 3BNC117-LS and nivolumab in adults on ART: a randomized double‑blind placebo‑controlled trial

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Nivolumab
  • Sponsor:Region Midtjylland

Mite allergy

Not yet recruiting

Efficacy of subcutaneous modified dust mite allergen extract in adults and children with allergic rhinitis/rhinoconjunctivitis due to house dust mites

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Probelte Pharma S.L.

Rheumatoid arthritis

Not yet recruiting

Methotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Abatacept
  • Sponsor:Aalborg University Hospital

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Mite allergy

Not yet recruiting

Standardization of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts and histamine dihydrochloride in skin testing for patients with dust mite allergy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dermatophagoides Farinae
  • Sponsor:Probelte Pharma S.L.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.